论文部分内容阅读
目的比较人附睾蛋白4(HE4)和糖链抗原125(CA125)对卵巢癌和盆腔良性疾病鉴别诊断的临床价值。方法用化学发光免疫分析法测定75例卵巢癌和80例盆腔良性疾病患者血清HE4和CA125水平。结果卵巢癌患者血清HE4和CA125水平显著高于盆腔良性疾病患者,差异有统计学意义(P<0.05)。血清HE4对卵巢癌的灵敏度(SEN)、特异度(SPE)和准确度分别为70.7%、91.3%和81.3%,血清CA125对卵巢癌的SEN、SPE和准确度分别为78.7%、81.3%和80.0%,血清HE4+CA125并联试验对卵巢癌的SEN、SPE和准确度分别为88.0%、78.8%和83.2%。HE4对Ⅰ期卵巢癌的灵敏度显著高于CA125,差异有统计学意义(P<0.05)。结论对卵巢癌和盆腔良性疾病的鉴别诊断,血清HE4优于CA125。
Objective To compare the clinical value of human epididymal protein 4 (HE4) and carbohydrate antigen 125 (CA125) in the differential diagnosis of ovarian cancer and pelvic benign disease. Methods The levels of serum HE4 and CA125 in 75 cases of ovarian cancer and 80 cases of pelvic benign disease were determined by chemiluminescence immunoassay. Results The levels of serum HE4 and CA125 in patients with ovarian cancer were significantly higher than those in patients with benign pelvic disease, the difference was statistically significant (P <0.05). The sensitivity, specificity and SPE of serum HE4 to ovarian cancer were 70.7%, 91.3% and 81.3%, respectively. The serum levels of SEN, SPE and accuracy of CA125 in ovarian cancer were 78.7% and 81.3%, respectively 80.0%, serum HE4 + CA125 parallel test for ovarian cancer SEN, SPE and accuracy were 88.0%, 78.8% and 83.2%. The sensitivity of HE4 to stage I ovarian cancer was significantly higher than that of CA125, the difference was statistically significant (P <0.05). Conclusion The differential diagnosis of ovarian cancer and pelvic benign disease, serum HE4 is superior to CA125.